Title: Emergency Drug Kits at the Danish Hospital Pharmacies: A Study of the Management and Challenges

Group: 10002 – 10th Semester 2018
Medicine with Industrial Specialization, Translational Medicine

Period: February 2018 – May 2018

ECTS: 30 points

Authors:
Stine Abildgaard Knudsen
Student Number: 20135841

Maria Christensen
Student Number: 20135749

Supervisor:
Anne Estrup Olesen, MSc.Pharm, Ph.D.

External supervisor:
Hanne Plet, MSc.Pharm, Ph.D.

Number of pages: 27

Number of appendices: 5

Number of appendix pages: 31

Number of characters: 74293
Preface

This master thesis was carried out at the Department of Health Science & Technology, Faculty of Medicine at Aalborg University in an external collaboration with the Hospital Pharmacy in the North Denmark Region. The thesis consists of a list of abbreviations, two theory chapters, and the main article. The first theory chapter, *Medicine for Cardiac Arrest*, describes and evaluates the current evidence for use of vasopressors and antiarrhythmics in cardiac arrest. The second theory chapter, *The Hospital Pharmacies and Their Collaboration with Amgros*, describes the functions of the hospital pharmacies in Denmark and the procurement process of pharmaceuticals through Amgros. The article, *Emergency Drug Kits at the Danish Hospital Pharmacies: A Study of the Management and Challenges*, focuses on the management of emergency drug kits at the hospital pharmacies and challenges hereof.
List of Abbreviations
AHA: American Heart Association
CPR: Cardiopulmonary resuscitation
EDK: Emergency drug kit
ERC: European Resuscitation Council
GDP: Good distribution practice
GMP: Good manufacturing practice
HDA: High dose adrenaline
HPN: Hospital Pharmacy in the North Denmark Region
MA: Meta-analysis
MIMI: The Danish executive order on manufacture and import of medicinal products and intermediate products
PDDM: The Danish executive order on prescriptions and dose dispensing of medicinal products
PEA: Pulseless electrical activity
pVT: Pulseless ventricular tachycardia
ROSC: Return of spontaneous circulation
RCT: Randomized controlled trial
SDA: Standard dose adrenaline
SR: Systematic review
VF: Ventricular fibrillation
**Medicine for Cardiac Arrest**

The following paragraphs describe the evidence of utilizing vasopressors and antiarrhythmics during out-of-hospital/in-hospital cardiac arrest. The selected literature is based on a high level of evidence (1), and the publication dates of all systematic reviews and meta-analyses must have been within the last 10 years (2009-2018). The paragraphs are based on one randomized controlled trial, two systematic reviews, six meta-analyses, and the two current guidelines from the American Heart Association (AHA) and the European Resuscitation Council (ERC), respectively.

One of the leading causes of death in Europe is sudden cardiac arrest, which yearly affects 350,000-700,000 individuals in the European countries (2,3). Cardiac arrest is a condition characterized by loss of effective cardiac output, and it is associated with four heart rhythms known as ventricular fibrillation (VF), pulseless ventricular tachycardia (pVT), pulseless electrical activity (PEA), and asystole (4,5). First-line treatment of cardiac arrest is cardiopulmonary resuscitation (CPR), and if the heart rhythm is shockable (VF/pVT), defibrillation is also recommended as first-line treatment. Pharmacological interventions with vasopressors, antiarrhythmics, and other drugs are second-line of treatment as the evidence for their effectiveness in cardiac arrest is limited (5-7).

**Vasopressors**

Whether or not to continue recommending vasopressors for resuscitation have been discussed greatly the recent years. The most common vasopressors include adrenaline and vasopressin, and the former has been widely used as first-line vasopressor agent for the four heart rhythms associated with cardiac arrest. Adrenaline is an α- and β-adrenergic agonist, and its vasoconstricting abilities is due to stimulation of α-adrenergic receptors, which increases coronary and cerebral perfusion pressure during CPR (6,8). The β-adrenergic effects are not advantageous during cardiac arrest as it increases myocardial oxygen consumption, myocardial oxygen imbalance, and cerebral vasoconstriction causing cerebral ischemia and unfavorable neurological outcomes (6).

Vasopressin, also known as antidiuretic hormone, has been proposed as an alternative to adrenaline (9). It is a neurohypophysial hormone and acts as a vasoconstrictor when binding to V1 receptors in vascular smooth muscle cells, and thereby increases inotropy along with systemic and coronary vasoconstriction. Compared to adrenaline, vasopressin is associated with i.a. less impairment of cerebral blood flow, less pulmonary constriction and a longer half-life (6). Nonetheless, vasopressin is also associated with adverse effects such as increased systemic vascular resistance and myocardial afterload.
The ERC and the AHA find it reasonable to administer 1 mg of adrenaline every 3-5 minutes during CPR (5,8). This reasoning is supported by reviews, which found that this dose of adrenaline is associated with increased return of spontaneous circulation (ROSC) and survival to hospital admission compared to placebo (9,10), but whether adrenaline is superior to vasopressin is inconclusive (9,11). Additionally, high doses of adrenaline (5-15 mg) compared to the standard dose are associated with increased ROSC and survival to hospital admission especially for patients with PEA and asystole; however, it is also associated with increased neurological side effects (9,10). In contrast, the majority of the systematic reviews and meta-analyses have found no differences between adrenaline, vasopressin, and placebo during cardiac arrest in terms of survival to hospital discharge and neurological outcome (6,9-11). Whether to combine adrenaline and vasopressin or use them in succession has been tested as well, but none of these improved the long-term survival compared to the drugs administered alone (6,10,12). One the contrary, when considering the subgroup of patients with asystole, vasopressin with or without adrenaline has been associated with significantly higher rates of ROSC and long-term survival compared to adrenaline alone, especially when administered within 20 minutes (6,11,12). Table A illustrates the main study outcomes of the above-mentioned studies regarding the use of vasopressors during cardiac arrest.

Because of different study designs, objectives, ethical dilemmas, and underpowered studies limited conclusions of whether vasopressors improve the outcome of cardiac arrest can be drawn (12). In order to determine whether the use of vasopressors is beneficial or harmful, randomized, placebo-controlled, double-blinded trials conducted on larger populations are required (10).

**Antiarrhythmics**

Before the publication of the ALIVE trial in 2002 (13), lidocaine was recommended as the first-line antiarrhythmic agent during shock-resistant VF or pVT (6). The results from the ALIVE trial revealed that administration of amiodarone significantly increased survival to hospital admission compared to lidocaine (13). Therefore, the latest versions of the AHA and ERC guidelines recommend amiodarone as a first-line antiarrhythmic agent (5,8). However, the use of antiarrhythmics in cardiac arrest is still questionable (6). Physiologically, amiodarone controls ventricular arrhythmias by blocking cardiac potassium channels, which increases the refractory period in the myocytes and decreases the atrioventricular conduction rate, which in turn allow the ventricles to repolarize. Apart from the beneficial effects, amiodarone is also associated with common side effects such as hypotension and bradycardia in patients with ROSC (5). The ERC and AHA recommend an intravenous dose of 300 mg amiodarone after three shock attempts with the defibrillator and a further dose of 150 mg after five shocks (5,8).
Lidocaine is a second-line antiarrhythmic agent, and it blocks the cardiac sodium channels and thereby increases the refractory period in the myocytes and raises the depolarization threshold, and thus minimizing the risk of early action potentials (5,8). Toxic doses of lidocaine can result in paresthesia, confusion, and convulsions, and therefore a low dose of lidocaine, such as 100 mg, after three shock attempts followed by an additional dose of 50 mg, if necessary, are considered appropriate according to the ERC guideline (5).

Even though the ALIVE trial found amiodarone to be superior to lidocaine in regard to survival to hospital admission (13), a systematic review concludes that amiodarone and lidocaine are equivalently superior to placebo regarding survival to hospital admission (2). Nevertheless, two other reviews conclude that there is no definite evidence that the administration of any antiarrhythmic agent significantly increase the occurrence of ROSC or survival to hospital admission compared to placebo (14,15). Evidently, there is no consensus regarding the effect on short-term survival after administration of an antiarrhythmic agent. Concerning the rate of survival to hospital discharge, the review by Khan et al. demonstrates superiority of lidocaine over amiodarone (15). One the contrary, other reviews generally agree that there are no significant differences between administration of an antiarrhythmic agent and placebo in terms of survival to hospital discharge and neurological outcome (2,6,14). This could be due to the fact that the studies included in the reviews were underpowered, and therefore not able to detect differences in long-term survival (2,6). Table B illustrates the main study outcomes of the above-mentioned studies regarding the use of antiarrhythmics during cardiac arrest.

The inconclusive evidence for the use of antiarrhythmics in cardiac arrest illustrates the necessity for further investigations with large multicentre randomized clinical trials examining both existing and future antiarrhythmic drugs (6).
Table A: Comparison of treatment outcomes for different combinations of adrenaline, vasopressin, and placebo. The greater than sign (> ) is used to indicate what drug (combination) the individual articles are supporting. A: Return of spontaneous circulation (ROSC), B: Survival to hospital admission, C: Survival to hospital discharge, and D: Neurological outcome. HDA: High dose adrenaline, MA: Meta-analysis, RCT: Randomized controlled trial, SDA: Standard dose adrenaline, and SR: Systematic review.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Included studies</th>
<th>Types of studies (quantity)</th>
<th>Intervention and control</th>
<th>Outcomes reported</th>
<th>Main study outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Interventional studies (12)</td>
<td>- Vasopressin vs. placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Observational studies (2)</td>
<td>- Adrenaline vs. vasopressin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline/vasopressin vs. adrenaline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- SDA vs. HDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Layek et al. (2014)</td>
<td>MA</td>
<td>10</td>
<td>- RCT (10)</td>
<td>- Adrenaline vs. vasopressin</td>
<td>A-D</td>
<td>Neutral: A-D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline/vasopressin vs. adrenaline/placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Vasopressin after adrenaline vs. placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin et al. (2014)</td>
<td>MA</td>
<td>14</td>
<td>- RCT (14)</td>
<td>- Adrenaline vs. placebo</td>
<td>A-D</td>
<td>Supporting: A-B (adrenaline &gt; placebo) (HDA &gt; SDA) Neutral: C-D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline vs. vasopressin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline/vasopressin vs. adrenaline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- SDA vs. HDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lundin et al. (2016)</td>
<td>SR</td>
<td>47</td>
<td>- Interventional studies (25)</td>
<td>- Adrenaline vs. placebo</td>
<td>A-D</td>
<td>Neutral: A-D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline vs. vasopressin</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline/vasopressin vs. adrenaline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- SDA vs. HDA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mentzelopoulos et al.</td>
<td>MA</td>
<td>6</td>
<td>- RCT (6)</td>
<td>- Adrenaline vs. vasopressin</td>
<td>A-D</td>
<td>Neutral: A-D</td>
</tr>
<tr>
<td>(2012)</td>
<td></td>
<td></td>
<td></td>
<td>- Adrenaline/vasopressin vs. adrenaline</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Vasopressin after adrenaline vs. adrenaline</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table B: Comparison of treatment outcomes for amiodarone, lidocaine, and placebo. The greater than sign (>) is used to indicate what drug (combination) the individual articles are supporting. A: Return of spontaneous circulation (ROSC), B: Survival to hospital admission, C: Survival to hospital discharge, and D: Neurological outcome. MA: Meta-analysis, RCT: Randomized controlled trial, and SR: Systematic review.

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Included studies</th>
<th>Types of studies (quantity)</th>
<th>Interventional and control</th>
<th>Outcomes reported</th>
<th>Main study outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chowdhury et al. (2018) (14)</td>
<td>MA</td>
<td>12</td>
<td>- RCT (4)</td>
<td>- Amiodarone vs. placebo</td>
<td>A-D</td>
<td>Neutral: A-D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Observational studies (8)</td>
<td>- Lidocaine vs. placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Amiodarone vs. lidocaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dorian et al. (2002) (13)</td>
<td>RCT</td>
<td>-</td>
<td>- Amiodarone vs. lidocaine</td>
<td></td>
<td>B-C</td>
<td>Supporting: B-C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(amiodarone &gt; lidocaine)</td>
<td></td>
<td>(amiodarone &gt; lidocaine)</td>
</tr>
<tr>
<td>Khan et al. (2017) (15)</td>
<td>MA</td>
<td>7</td>
<td>- RCT (3)</td>
<td>- Amiodarone vs. placebo</td>
<td>A-C</td>
<td>Supporting: C</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Observational studies (4)</td>
<td>- Lidocaine vs. placebo</td>
<td></td>
<td>(Lidocaine &gt; amiodarone)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Amiodarone vs. lidocaine</td>
<td></td>
<td>(Lidocaine &gt; placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neutral: A-B</td>
</tr>
<tr>
<td>Lundin et al. (2016) (6)</td>
<td>SR</td>
<td>6</td>
<td>- RCT (2)</td>
<td>- Amiodarone vs. placebo</td>
<td>C-D</td>
<td>Neutral: C-D</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Observational studies (4)</td>
<td>- Lidocaine vs. placebo</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Amiodarone vs. lidocaine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sanfilippo et al. (2016) (2)</td>
<td>MA</td>
<td>7</td>
<td>- RCT (3)</td>
<td>- Amiodarone vs. placebo</td>
<td>B-D</td>
<td>Supporting: B</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>- Observational studies (4)</td>
<td>- Lidocaine vs. placebo</td>
<td></td>
<td>(amiodarone &gt; placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Amiodarone vs. lidocaine</td>
<td></td>
<td>(lidocaine &gt; placebo)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neutral: C-D</td>
</tr>
</tbody>
</table>
References


The Hospital Pharmacies and Their Collaboration with Amgros

Medicine utilized in medical emergencies such as cardiac arrest or anaphylactic shock can be combined into emergency drug kits (EDK). The kits include all the vital medications and utensils necessary for specific emergencies and may in some situations be the difference between life and death (1,2). The hospital pharmacies in Denmark produce and distribute EDKs to the public hospitals and other customers as a service in exchange for payment (1,3). At present, eight hospital pharmacies are situated within the five regional authorities in Denmark (Fig. A), and they are funded by the state and managed by the Danish regions (4,5).

Figure A: The eight hospital pharmacies in Denmark. The white dots illustrate the locations of the hospital pharmacies in the different regions. Modified from (4,6).

Besides packing EDKs to the public hospitals, the hospital pharmacies also distribute a standard assortment of pharmaceuticals to the hospitals. Further, they manufacture hospital-specific drugs and deliver services within clinical pharmacy (7-9). Common for all the hospital pharmacies is that they procure about 99% of the drugs utilized at the public hospitals through a pharmaceutical procurement organization called Amgros (4).

Amgros is funded by the state and managed by the Danish regions as well. By centralizing the procurement of pharmaceuticals into one company, Amgros creates economies of scale for the regions without compromising quality and patient safety. In 2016, the Danish regions saved DKK 2.8 billion due to the procurement process by Amgros and the savings increase yearly (4). Annually, Amgros invites to submit bids for the supply of drugs to the hospitals through competitive tendering.
The entire tendering process is accomplished through an online tendering system, in which the suppliers make an offer on the pharmaceuticals on call. Apart from the price of the drug, factors such as the quality, consistency, and effectiveness of the drug are also considered in the tendering process (10). The supplier, who wins the contract, must supply the hospitals for the period stated in the contract (11). The public procurements are regulated by the EU Public Procurement Directive and the Danish Public Procurement Act. Normally, procurement of goods in the EU must exceed a threshold value of DKK 1.5 million to initiate a tender round; however, to ensure competition Amgros makes EU calls for tenders for purchases exceeding a value of DKK 500,000 (12). The drugs purchased by Amgros at a discounted price are part of a supply chain involving several steps (13) (Fig B). First, the hospitals predict a demand and then order the drugs at the local hospital pharmacy. In some cases, the hospital pharmacies manufacture the drugs themselves, such as total parenteral nutrition, cytostatics, and coupled antibiotics. Otherwise, they place the orders to Amgros through ApoVision, an online system for monitoring economics, stock, and logistics (14). Subsequently, Amgros forwards the orders to the supplier or wholesaler, who delivers the drugs to the hospital pharmacies. The hospital pharmacies are in charge for distributing the drugs to the hospital wards (13).

**Figure B:** The drug supply chain. The supply chain illustrates the interaction between the different operators including the hospital, the hospital pharmacy, Amgros, and the supplier/wholesaler (4,13,15,16).

![Drug Supply Chain Diagram](image)

**References**

2. Rosenberg M. Preparing for medical emergencies: The essential drugs and equipment for the dental office. American Dental Association 2010 May;141 Suppl 1:14S-9S.


Emergency Drug Kits at the Danish Hospital Pharmacies: A Study of the Management and Challenges

Stine Abildgaard Knudsen and Maria Christensen

Department of Health Science & Technology, Faculty of Medicine, Aalborg University, Denmark.

Introduction: Access to emergency drug kits (EDKs) during medical emergencies can be life-saving; however, recent doubts about the quality of the kits have been expressed. Additionally, the Hospital Pharmacy in the North Denmark Region (HPN) does not currently have an effective method to manage the Amgros-tender in relation to the EDKs even though this can be a major challenge.

Objectives: The first objective was to determine and compare the management of EDKs at the hospital pharmacies in Denmark, whereas the second objective was to ease the decision-making of whether it is worthwhile for the HPN to comply with the Amgros-tender in relation to the EDKs.

Methods: The hospital pharmacies in Denmark were enrolled in a cross-sectional study. Information about the management and challenges of the EDKs was inquired by the means of a questionnaire developed for this purpose. The responses were analyzed by thematic analysis and simple statistics, and the results were used to create a tool able to manage drug replacements in the EDKs.

Results: All eight hospital pharmacies completed the questionnaire, and the distribution between single-use and reusable packaging is nearly equal. The hospital pharmacies comply with a variation of regulations of which good distribution practice is the most common. Six hospital pharmacies experience challenges with drug replacements in the EDKs and only one hospital pharmacy complies completely with the Amgros-tender. The majority of the hospital pharmacies use parameters such as price of the new drug and potential expense for new packaging in their decision of whether to comply with the Amgros-tender. To ease this decision, a tool able to calculate the economic outcomes of drug replacements in the EDKs was created.

Conclusion: The management of the EDKs varies greatly among the hospital pharmacies, and national requirements are therefore encouraged to ensure the quality. The challenges experienced with drug replacements reflect that complying with the Amgros-tender can be troublesome. A tool was created to ease the decision of whether it is worthwhile for the HPN to comply with the Amgros-tender for the EDKs.

Introduction

A medical emergency such as cardiac arrest or anaphylactic shock can be life-threatening, and the outcome often depend on access to relevant drugs and utensils (1,2). Therefore, keeping the essential drugs and utensils in a ready-to-use kit can make the difference between life and death (3). Kits of this sort are often referred to as emergency drug kits (EDKs) and are in Denmark produced by the hospital pharmacies (4). Beyond that, the hospital pharmacies also distribute the EDKs to the public hospitals ensuring that the healthcare providers have easy access to the necessary remedies during emergencies. As quality and patient safety are of utmost importance in the healthcare system, these are ensured by standardized working
procedures based on regulative requirements; however, no national requirements for the management of EDKs are declared (5,6). Therefore, the regulations the hospital pharmacies adhere to and what packaging they use etc. may be distinctly different resulting in EDKs of varying qualities. This concern is strengthened by critical deviations related to quality observed for the EDKs at the Hospital Pharmacy in the North Denmark region (HPN), indicating a need of improvement in this area. To ensure high quality of the kits across the hospital pharmacies in Denmark, national requirements standardizing the management of EDKs are needed. To achieve this, firstly it is necessary to determine and compare the management of EDKs at the hospital pharmacies in Denmark, which in the future renders it possible to develop the most effective standardized working procedures in this regard.

Most of the drugs used at the public hospitals including the drugs in the EDKs are annually subjected to a tender round, where Amgros invites to submit bids for the supply of drugs (7). Given the fact that Amgros is owned and managed by the five Danish regions (8), the hospital pharmacies are expected to buy the discounted drugs through Amgros. Buying the drugs through Amgros and always replacing them after a new tender is in this study defined as complying with the Amgros-tender. However, compliance with the Amgros-tender can be a major challenge in relation to the EDKs. Even though the Amgros-tender results in great savings for the Danish healthcare system in an overall perspective (7), replacement of the drugs in the EDKs do not always end in cost-reductions. This is due to the fact that drug replacements can be a comprehensive, time-consuming, and expensive procedure, as it requires procurement of the new drug, potential procurement of new packaging along with additional quality assurance etc. (9). If complying with the Amgros-tender becomes too comprehensive, the hospital pharmacies must increase the prices of the EDKs, and as a result the hospitals may discontinue to purchase them. This may cause the hospitals to resort to other options than the quality assured EDKs from the hospital pharmacies, which will diminish the patient safety, and thereby minimize the chance of a positive outcome of the emergency (10, 11). Due to the numerous challenges with the EDKs, the hospital pharmacies are required to decide whether it will be worthwhile to comply with the Amgros-tender for the EDKs. Nonetheless, the HPN does not currently have an effective method for this decision-making indicating an area with improvement potential.

Study Aim

The first objective of the thesis was to determine and compare the management of EDKs at the hospital pharmacies in Denmark, whereas the second objective was to ease the decision-making of whether it is worthwhile for the
HPN to comply with the Amgros-tender for the EDKs. The first objective was accomplished by developing a questionnaire about the EDKs and analyzing the responses thereof. The second objective was accomplished by applying knowledge obtained from the questionnaire and employees at the HPN to create a tool able to facilitate the economic outcomes of drug replacements in the EDKs.

**Methods**

**Study Design and Participants**

The eight hospital pharmacies in Denmark were invited to participate in the cross-sectional study, and they were informed that participation was voluntary and non-anonymous. Emails were sent to the administrative personnel of the hospital pharmacies, who helped uncover the most qualified employees for completing the questionnaire. An email with a description of the study and the link to the online questionnaire were sent to the respective employees. Furthermore, their assortment of EDKs and the content thereof were requested. The hospital pharmacies were compensated by non-monetary means in the form of a summary of the study results after end of study.

The respondents had a deadline of nine workdays to complete the questionnaire. In case of missing responses, the hospital pharmacies were contacted after nine workdays and if necessary fourteen.

**Unstructured Interviews**

In order to acquire first-hand knowledge of the EDKs, unstructured interviews with employees from the HPN were carried out. The interviews were conducted with the use of thematic questions, but without a complete interview guide. The responses, documented either by hand or on a computer, were utilized without subsequent thematic analysis. The economics of the EDKs and challenges thereof were discussed with the hospital pharmacist and the production manager. The employees working in the EDK production provided the authors with an awareness of the challenges occurring in the production during drug replacements, and a quality assurance specialist explained the regulatory requirements and her role in ensuring the quality of the EDKs.

**Development of Questionnaire**

A quantitative and qualitative methodology was applied in the form of a questionnaire to determine the management of EDKs at the hospital pharmacies (12). The questionnaire was developed specifically for this study by the means of the knowledge from the unstructured interviews. It was developed with consideration to unambiguous and appropriate phrasing, the type of questions along with time demands of the respondents (13-15). The questionnaire consisted of two forms and contained mainly closed-ended questions in the form of multiple response, multiple choice, and yes/no questions along with a few open-ended questions.
The first form contained general questions about the packaging of EDKs, customers, feedback, and the adherence to regulations (Appendix I). The second form contained questions about challenges with the EDKs in relation to the Amgros-tender and their working procedure for drug replacements in the EDKs. The questionnaire was estimated to take 15 minutes to complete, and combined, the two forms contained 13 main questions. Depending on the respondents’ answers to those, they received further sub-questions. The questionnaire was developed in the online data management platform, SMART-TRIAL (Version 2.6, MEDEI ApS, Aalborg, Denmark) and a free subscription was granted.

Before the initiation of the study, the questionnaire was subjected to a pilot study conducted on five employees at the HPN (16). Based on their responses and feedback, the questionnaire was subsequently revised.

**Processing of the Questionnaire**

A qualitative data analysis in the form of thematic analysis was performed to analyze the responses of the open-ended questions. Coding categories were developed based on the thematic content of the responses. Subsequently, each response was labelled with one or more codes, which was used to identify patterns and themes enabling quantifiable interpretation of the responses (17,18).

A quantitative data analysis in the form of simple counts were applied for the responses of both the closed-ended and open-ended questions (19). If the hospital pharmacies were unable to provide some of the requested information, it was considered missing and therefore not included in the analyses. The figures used to illustrate the results were created in either draw.io (Version 8.6.8, Northampton, UK) or SPSS (Version 25.0, IBM Corp., New York, USA) and modified in the image processing program, GIMP (Version 2.8.22, 2017). Only the pertinent questions from the questionnaire were included in the analyses.

**Development of an Economic Calculation Tool for EDKs**

To ease the decision-making of whether it is worthwhile to comply with the Amgros-tender for the EDKs, a tool was created to facilitate the economics of drug replacements in the EDKs. Knowledge from the questionnaire and the unstructured interviews was used to establish the important economic parameters of drug replacements (Fig. 1). These parameters were utilized to create functions able to calculate the economic outcomes of drug replacements (Appendix II). The functions were entered in a Microsoft Excel® spreadsheet (Version 16.0, 2016 MSO USA), in which the input-cells were subjected to data validation, whilst the rest of the cells were protected to avoid modifications. The tool was phrased in Danish and the ease of use was assessed by two employees at the HPN. The reliability of the tool was tested through test cases.
Figure 1: Economic parameters of drug replacements. The figure illustrates the parameters of the tool that the user must fill-in. They are divided into parameters related to the current drug, the new drug along with general parameters. The values of the parameters written in italics are entered in advance in the tool but can be altered if necessary. EDK: Emergency drug kit.

Results
All eight hospital pharmacies in Denmark completed the questionnaire. It was completed twice in the Central Region, since the production of EDKs is allocated to two separate pharmacy departments. The two responses from the Central Region were combined, resulting in a total of eight respondents. The majority of the responses are presented in the following sections, while the rest are accounted for in Appendix III. All results are presented as quantity of hospital pharmacies.

Packaging
All eight hospital pharmacies responded that they produce EDKs and that the assortment and contents of the kits are selected in collaboration between the hospital pharmacies, the hospitals, and specialists assigned by the Regional Drug Committees. The quantity of hospital pharmacies that produce either single-use or reusable EDKs is nearly equal (Fig. 2A). Only one hospital pharmacy produces both single-use and reusable EDKs. After usage of the single-use kits, the packaging along with the

Figure 2: EDK packaging A) illustrates the quantity of hospital pharmacies that package single-use EDKs, reusable EDKs or both. B) illustrates the distribution of single-use and reusable packaging for the different types of EDKs among the hospital pharmacies. The Mixed EDKs category covers EDKs that contain drugs used for multiple types of emergencies. EDK: Emergency drug kit.
remaining drugs are discarded, whereas the packaging and the remaining drugs are reutilized in the reusable kits.

The hospital pharmacies were asked to state why they produce single-use EDKs or reusable ones. The most common reason for using single-use EDKs was quality assurance, as the hospital pharmacies cannot ensure that reusable EDKs are managed correctly at the hospitals e.g. stored at a proper temperature (Fig. 3). It was also stated that single-use EDKs are preferable as they require less working capacity related to administration and repacking of the EDKs along with no cleaning procedures. The most common argument for reusable EDKs is that they are more resource efficient in terms of reduced discard of drugs and utensils and recycling of the packaging, which allows the hospital pharmacies to sell the EDKs at a low price.

Even though the distribution of hospital pharmacies that produce single-use EDKs and reusable EDKs is nearly equal, the majority of the produced EDKs are reusable (Fig. 2B). In addition, for the individual types of EDKs, the distribution between single-use and reusable packaging is varying. For instance, the packaging for anaphylactic shock and convulsions are mainly single-use, whereas the packaging for EDKs like anesthesia along with pregnancy and birth is mainly reusable. An elaboration of the EDKs are available in Appendix III.

In relation to the production of EDKs, some hospital pharmacies produce multiple EDKs for the same type of emergency. This is because some EDKs have been regionalized, whereas others are still produced for specific hospitals and wards. For example, even though two hospital pharmacies produce EDKs for convulsions (Fig. 2B), one of them produce three different kits to the hospitals within that region.

**Regulatory Compliance**

The hospital pharmacies stated which regulation or combination of regulations they adhere to in their management of EDKs (Fig. 4). The responses were diverse as they use between one and four regulations in five different combinations; however, good distribution practice (GDP) is the most common regulation regardless of what packaging the hospital pharmacies use. Even though the hospital pharmacies are obligated to comply with all aspects of the regulations they adhere to, employees at the HPN indicated that they only comply with some as-
Figure 4: The use of regulations with respect to packaging. The figure illustrates the combinations of regulations that are used in the management of EDKs at the hospital pharmacies coupled with the packaging they use. EDK: Emergency drug kit, GDP: Good distribution practice, GMP: Good manufacturing practice, MIMI: The Danish executive order on manufacture and import of medicinal products and intermediate products, and PDDM: The Danish executive order on prescriptions and dose dispensing of medicinal products.

pects. This might also apply to the other hospital pharmacies, and since they were not asked to specify what aspects they comply with, it is unknown whether they comply with all aspects of the selected regulations or solely some of them.

Challenges of Drug Replacements and Compliance with the Amgros-Tender
Six hospital pharmacies reported that they experience challenges with drug replacements in the EDKs, with the most common challenges being packaging problems and additional labor costs (Fig. 5). Five out of the six hospital pharmacies that experience drug replacement challenges comply conditionally with the Amgros-tender, whereas one hospital pharmacy complies completely with the Amgros-tender, meaning that they replace the drugs in the EDKs according to the new tender. The last two hospital pharmacies do not experience any challenges in this regard. One of them complies conditionally with the Amgros-tender, whilst the other does not comply at all. No compliance indicates that the drugs in the EDKs are exclusively replaced, when they are about to expire or the stock is spent. In relation to drug replacements occurring after the Amgros-tender, none of the hospital pharmacies recall the EDKs to replace the drugs before expiration of the kits.
Figure 5: Drug replacement challenges in the EDKs. The figure illustrates the challenges (experienced by six of the hospital pharmacies) of drug replacements along with their degree of compliance with the Amgros-tender. * includes challenges with drug shortage, non-registered branded products and relocation of drugs in the EDKs each experienced by one hospital pharmacy. EDK: Emergency drug kit.

Parameters for Drug Replacements
The hospital pharmacies were asked to state which parameters they include in their decision-making regarding drug replacements in the EDKs. The six hospital pharmacies that comply conditionally with the Amgros-tender apply relevant parameters to decide whether to perform drug replacements (Fig. 6).

Figure 6: Parameters for drug replacements. The figure illustrates the most common parameters used in the decision-making of whether to comply with the Amgros-tender in the EDKs for the six hospital pharmacies that comply conditionally with the Amgros-tender. EDK: Emergency drug kit.
Potential expense for new packaging along with price of the new drug are the most common parameters used by six of the hospital pharmacies in their decision-making. In fact, three out of six hospital pharmacies reported that the applicability of the current packaging is a critical parameter for complying with the Amgros-tender. In addition, the majority of the hospital pharmacies also apply other relevant parameters such as price of the current drug in new Amgros-period and predicted yearly demand of the drug in their decision-making.

Economic Calculation Tool for EDKs

The Microsoft Excel-spreadsheet constitutes the economic calculation tool for EDKs. The tool along with instructions for use created for the HPN are available in Appendix IV and Appendix V, respectively. The tool provides the total costs of keeping the current drug and replacing the current drug with the new drug. The difference between these two costs equals the savings or additional costs for the drug replacement. The reliability of the tool was confirmed through test cases.

Appendix IV provides a real example of the total costs of a drug replacement, which was considered too expensive by the HPN to complete. The example provides the costs of replacing Solu-Medrol® with Depo-Medrol® in the EDK for anaphylactic shock. The greatest additional costs for the drug replacement are illustrated in Table 1.

Table 1: The greatest additional costs of replacing Solu-Medrol® with Depo-Medrol®.

<table>
<thead>
<tr>
<th>Additional costs</th>
<th>DKK</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drug price</td>
<td>165,450.00</td>
</tr>
<tr>
<td>Labor costs</td>
<td>16,050.00</td>
</tr>
<tr>
<td>Total</td>
<td>183,000.00</td>
</tr>
</tbody>
</table>

Discussion

The current study established that the management of packaging, regulatory compliance, and the Amgros-tender in relation to the EDKs vary greatly among the eight hospital pharmacies in Denmark. Furthermore, an Excel-based tool was created to ease the decision-making of whether to comply with the Amgros-tender in the EDKs.

Each hospital pharmacy selects the assortment and contents of the EDKs in collaboration with the hospitals and specialists assigned by the Regional Drug Committees. This results in variation of the EDKs across the hospitals both within and among the regions. Nevertheless, as the former Ministry of Health and Prevention stated that patients are entitled to receive the same treatments independent of location (20), the EDKs should be standardized as well. This is further supported by the fact that the Danish Medicines Council has created national treatment guidelines to ensure homogenous treatments of high quality throughout the hospitals in Denmark (21). Further, if healthcare professionals work at different hospitals with dissimilar EDKs (22), the variation
within the kits may cause confusion during an emergency, and therefore potentially compromise the patient safety. Additionally, as some hospitals have specific requests for the contents of the kits, some hospital pharmacies produce multiple hospital-specific EDKs for i.a. cardiac arrest. This is a resource-demanding process compared to the production of one regionalized EDK for cardiac arrest, which is the reason the HPN strives to only produce regionalized EDKs (4,23). Based on this, establishment of a national drug committee that regularly updates national guidelines for the assortment of EDKs and their contents based on medical evidence is encouraged by the authors.

Further, these guidelines should also standardize the packaging of the kits. Currently, there is no consistency of whether the hospital pharmacies utilize single-use or reusable packaging for the different types of EDKs. Concerning the environment, reusable EDKs are a great advantage, as apart from reusing the packaging, the unused drugs can be included in the kits again (24). This renders it possible to sell the EDKs at a low price, which is highly relevant, as the hospitals have declined the EDK service in the past due to high prices. To ensure patient safety, it is critical that the hospitals utilize the quality assured EDKs from the hospital pharmacies (4). Further, the fact that the majority of the EDKs are reusable support the statement that the hospitals find them preferable. Nonetheless, the greatest advantage of single-use EDKs is that they simplify the process of fulfilling the regulatory requirements of good manufacturing practice (GMP) or GDP (25-27). In relation to resale of reusable EDKs, it is in the GMP and GDP required that the drugs have been transported, stored, and handled in compliance with the specific requirements to ensure the quality of the returned kits. As this would be extremely extensive to ensure and document, the U.S. Food and Drug Administration along with the British Medical Association state that the quality cannot be guaranteed after the drugs have left the hospital pharmacy and must therefore not be resold (28,29). Taking these statements into account, it is evident that by using single-use packaging compared to reusable, it is easier to comply with GMP and GDP to ensure quality and thereby patient safety. This could be the reason that four hospital pharmacies choose solely to produce single-use EDKs. Interestingly, the majority of the hospital pharmacies that package reusable EDKs stated that GMP or GDP are part of the regulations that they adhere to. Nonetheless, as it is unknown which aspects of the GMP and GDP the hospital pharmacies adhere to, it is uncertain if they meet the strict requirements of these regulations related to reselling of drugs. Besides the reselling aspect, the four regulations differ in several ways of which one of the most important aspects is the quality management system. In the GMP, GDP, and the Danish executive order on manufacture and import of medicinal products and intermediate products (MIMI) it is required
that self-inspections and audits are performed of the medicinal products to ensure the quality, whereas this aspect is not covered in the Danish executive order on prescriptions and dose dispensing of medicinal products (PDDM) (25,27,30,31). In relation to storage, only the GMP, GDP, and PDDM include specific requirements for parameters such as temperature, light, and humidity; however, when considering the transportation aspect, GMP and GDP are the only regulations covering this. Nevertheless, it is reasonable that the regulations do not cover the same aspects as they are created for different purposes. Still, due to their differences and the fact that the requirements of what the EDKs must fulfill is not specified anywhere, it might result in inconsistency of the quality of the kits among the hospital pharmacies. Therefore, future investigations should be aimed at examining which requirements the EDKs must fulfill in order to ensure quality and patient safety and provide the basis of a national decision.

**Compliance with the Amgros-Tender**

In theory, the hospital pharmacies are required to buy the drugs through Amgros, as they are both publicly owned (8). Therefore, if the hospital pharmacies do not support Amgros, it is not reasonable for the Danish state to fund the company. In practice, however, complying with the Amgros-tender in relation to the EDKs can be troublesome. This is reflected by the fact that only one of the hospital pharmacies complies completely with the Amgros-tender and that six hospital pharmacies experience challenges with drug replacements in the EDKs. As it is shown in the example in *Economic Calculation Tool for EDKs*, drug replacements in the EDKs can be an expensive procedure. From the example, it is evident that procurement of the new drug along with the labor costs were great expenses. For that reason, these parameters are frequently applied in the decision-making of whether to replace the drugs in the EDKs according to the new Amgros-tender. Even though the price per unit is cheaper for the new drug compared to the current drug, procurement of the new drug can be expensive. This is owed to the fact that the hospital pharmacies must buy an additional quantity of the new drug due to an exchange of the non-expired current drug in the expired/used EDKs. Discard of the non-expired drug is often a great expense as well, which is reflected by the fact that approximately half of the hospital pharmacies use *expiry of the current drug in stock* along with *expiry of the current drug in the EDKs* when deciding whether to comply with the Amgros-tender.

Moreover, single-use packaging allows for easier compliance with the Amgros-tender, as it is often made of cardboard, which is cheaper to purchase compared to the hard plastic packaging frequently used for reusable EDKs (32).

Given the many parameters influencing the costs of a drug replacement, determining
whether it is worthwhile to comply with the Amgros-tender can be complicated, and therefore it is relevant to assess how to facilitate the decision. The economic calculation tool for EDKs was designed with consideration to the above-mentioned parameters to facilitate this decision. In order to get maximum benefit from the tool, the hospital pharmacies must establish cut-off points determining how much is reasonable to pay for replacing drugs in the EDKs (33). The hospital pharmacist at the HPN finds an additional cost of DKK 20,000 for a drug replacement acceptable; however, it is unknown whether the other hospital pharmacies have established cut-off points. If the outcome of the tool results in additional costs beyond the cut-off point, it is reasonable to contact Amgros and explain that the price of the new drug does not provide enough savings to make the drug replacement worthwhile. This might provide incentive to find a solution satisfying for both parties. It could involve carrying out tender rounds less frequently, as this will avoid the yearly procurement of the new drugs for every EDK and decrease the labor costs. In addition, it would be beneficial for both Amgros and the supplier, who wins the contract for an extended period (34). In contrast, it must be considered whether this option reduces the competition (35), and thereby results in less savings for the Danish regions.

Another important aspect is the patient safety. None of the hospital pharmacies recall the EDKs before their expiry date, and therefore the drug replacements do not occur in the beginning of the new Amgros-period for all the kits. This can result in circulation of multiple brand names among the EDKs and lack of similarity with the brand names utilized at the hospital wards, which can be problematic regarding patient safety (36). To increase the patient safety, it is preferable to recall the EDKs when implementing new Amgros-tenders, even though it would be financially demanding.

### Study Strengths and Limitations

As the interviews with the employees of the HPN were not recorded, the responses were not transcribed nor analyzed by thematic analysis. This was considered a study limitation along with the fact that the interviews were performed without an interview guide (37,38).

An online questionnaire was chosen to inquire information from the hospital pharmacies as it eases the time demands of the respondents and provide the option of completing the questionnaire when convenient (39). The questionnaire was designed through the SMART-TRIAL platform to ensure a seamless user experience (40). Furthermore, as it was designed to display questions based on the previous responses, only relevant questions were presented to the respondents. Limitations of the questionnaire included the risk of the respondents misunderstanding the questions (41). Despite that the questionnaire was thoroughly evaluated by the authors and five employees at the HPN, some of the responses gave the
impression that a few questions had been misunderstood. This is a common obstacle when developing a questionnaire compared to utilizing a standardized one. Further, as each hospital pharmacy was represented by one employee, it is relevant to consider that they might not have had the knowledge to answer each question satisfactory due to the diverse nature of the questions.

The economic calculation tool for EDKs covers the future costs of drug replacements, and therefore expenses such as discard of the current drug was not included in the tool. Further, as the tool was created for the purpose of this study, it has not been validated previously, which was considered a study limitation. Nevertheless, the reliability of the tool was confirmed through test cases, and the ease of use was assessed and approved by two employees at the HPN to ensure that it is suitable for the work environment at the HPN. Another consideration is that the tool was created for drug replacements occurring annually. Therefore, if the supply contract does not last exactly one year, the tool cannot be utilized as the outcome will be misleading. At last, it is relevant to mention that the tool solely provides the economic outcomes of a drug replacement and does not determine whether to perform the drug replacement. Consequently, as the tool only assists in the decision-making process, the hospital pharmacies must make the final decision themselves and consider the aspect of patient safety as well.

**Conclusion**

From the responses of the questionnaire developed for this study, it was evident that the management of the EDKs varies greatly among the hospital pharmacies in Denmark. This includes the packaging of the EDKs and the regulations the hospital pharmacies adhere to. Even though reusable EDKs provide great advantages, it is concluded that single-use EDKs provide the best chances of ensuring quality and patient safety. Further, in order to ensure the quality of the EDKs nationwide, national requirements specific for the EDKs are encouraged. Additionally, the majority of the hospital pharmacies experience challenges with drug replacements in the EDKs reflecting that compliance with the Amgros-tender can be troublesome. Most of the hospital pharmacies include parameters such as *price of the new drug* and *potential expense for new packaging* in their decision of whether to comply with the Amgros-tender. To facilitate the decision-making process, the present study utilized these parameters to create a tool able to calculate the economic outcomes of drug replacements. As this tool provides information about the additional costs or savings, it eases the decision of whether it is worthwhile for the HPN to comply with the Amgros-tender for the EDKs.

**Acknowledgements**

The authors would like to thank Anne Estrup Olesen, MSc.Pharm, Ph.D. from Mech-Sense.
for inspiring supervision throughout the thesis. We thank Hanne Plet, MSc.Pharm, Ph.D. from the Hospital Pharmacy in the North Denmark Region for external supervision and for providing the opportunity to perform this study. Furthermore, we are grateful for the knowledge and assistance provided by Gitte Søndergaard, the hospital pharmacist; Solveig Bang Lyngsø, BSc.Pharm; Janne Jensen, MSc.Pharm; Anne Brejnholt, MSc.Pharm, and the employees from the EDK production all from the Hospital Pharmacy in the North Denmark Region. A special thanks to all the hospital pharmacies in Denmark for participating in the study. At last, we would like to thank MEDEI ApS for the free subscription of SMART-TRIAL.

References

2. Rosenberg M. Preparing for medical emergencies: The essential drugs and equipment for the dental office. American Dental Association 2010 May;141 Suppl 1:14S-9S.
18. O’Cathain A, Thomas KJ. "Any other comments?" Open questions on questionnaires - a bane or a bonus to research? BMC Medical Research Methodology 2004 Nov 8;4:2288-4-22.
35. Marques RC, Berg S. How does opportunism affect performance under


Appendix I - Questionnaire

The following links provide access to the online questionnaire containing the two forms. A printed version with all the main and sub-questions is available below; but as the questionnaire is constructed in such a way that the sub-questions are dependent on the responses of the main questions, the online questionnaire provides a better understanding of the principle.

Link for internal supervisor
- https://app.smart-trial.co/#/public/5a83de330085561654d90c99/HnBQZDlRxsiSKxYCxxTeFrZgaXiuLmu

Link for censor
- https://app.smart-trial.co/#/public/5a83de330085561654d90c99/ibszGct5GjvW3WnrZQUfPJVgdkyWtc98

Link for external supervisor
- https://app.smart-trial.co/#/public/5a83de330085561654d90c99/YT9JPPo1y9ZkYzZmwQxZq8B6I7gNnUfQ
Form: 1. Akutbakker

_Akutbakker_ refererer til bakker/kasser med lægemidler og sygeplejeartikler, der anvendes i akutte situationer såsom hjertestop. Alle spørgsmålene skal besvares, før spørgeskemaet kan gemmes.

<table>
<thead>
<tr>
<th>Pakker i akutbakker?</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Ja</td>
</tr>
<tr>
<td>☐ Nej</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Har I tidligere pakket akutbakker?</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐ Ja</td>
</tr>
<tr>
<td>☐ Nej</td>
</tr>
</tbody>
</table>
Hvilke akutbakker pakked I?

<table>
<thead>
<tr>
<th>Akutbakker</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Ja</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Anafylaktisk shock</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Hjertestop</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Kramper</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Psykiatri</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Operation (anæstesi)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Akut patienttransport</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○</td>
</tr>
</tbody>
</table>
Hvis I pakkede andre akutbakker, bedes I venligst angive dem

Hvorfor har I stoppet pakningen af akutbakker?

Kommenter evt. på parametre som pris, manglende efterspørgsel og manglende kapacitet på sygehusapoteket
Hvem beslutter sortimentet og indholdet af akutbakkerne?

Pakker I akutbakker til andre kunder end sygehusene?

☐ Ja

☐ Nej

Hvilke andre kunder pakker I akutbakker til (f.eks. Falck og hospice)?
Pakker I akutbakker til engangsbrug?

- Ja
- Nej

Genbruger I emballagen af engangs-akutbakkerne?

- Ja
- Nej

Hvilke akutbakker pakker I til engangsbrug?

- Anafylaktisk shock
- Hjertestop
- Kramper
- Psykiatri
- Operation (anæstesi)
- Akut patienttransport
- Andre akutbakker
Hvilke andre akutbakker pakker I til engangsbrug?

Hvorfor har I valgt at pakke akutbakker til engangsbrug?

Kommenter evt. på parametre som patientsikkerhed, forbrug af indhold i bakken, kvalitetssikring og ønske fra kunde

Pakker I akutbakker til færgangsbrug?

- Ja
- Nej
Hvilke akutbakker pakker I til flergangsbrug?

- [ ] Anafylaktisk shock
- [ ] Hjertestop
- [ ] Kramper
- [ ] Psykiatri
- [ ] Operation (anæstesi)
- [ ] Akut patienttransport
- [ ] Andre akutbakker

Hvilke andre akutbakker pakker I til flergangsbrug?
Hvorfor har I valgt at pakke akutbakker til flergangsbrug?

Kommenter evt. på parametre som patientsikkerhed, akutbakkepris, forbrug af indhold i bakken, kvalitetssikring, ønske fra kunde

Har I modtaget tilbagemeldinger fra kunderne vedr. akutbakkerne?

- Ja
- Nej
Hvad fik I tilbagemeldinger om?

- [ ] Tydelige etiketter på akutbakkerne
- [ ] Problemer med etiketter på akutbakkerne
- [ ] Ønske om flere etiketter på akutbakkerne
- [ ] Overskuelig placering af lægemidler i akutbakkerne
- [ ] Uoverskuelig placering af lægemidler i akutbakkerne
- [ ] Risiko for forveksling af lægemidler
- [ ] Andet

Hvilke andre parametre fik I tilbagemeldinger om?

...
Hvilke retningslinjer/bekendtgørelser følger i ift. pakning og håndtering af akutbakker?

- Good manufacturing practice (GMP)
- Good distribution practice (GDP)
- Bekendtgørelse om recepter og dosisdispensering af lægemidler
- Bekendtgørelse om fremstilling og indførsel af lægemidler og mellemprodukter
- Andre retningslinjer/bekendtgørelser

Afkryds gerne flere felter, hvis I arbejder efter en kombination af flere retningslinjer

Hvilke andre retningslinjer/bekendtgørelser følger i ift. akutbakkerne?
Har I nogle kommentarer eller tilføjelser?

Venligst angiv e-mailadresse og telefonnummer på en kontaktperson, således vi har mulighed for at stille afklarende spørgsmål
Form: 2. Håndtering af Amgros-udbud i akutbakkerne

Dette spørgeskema skal kun besvares, hvis I pakker akutbakker. Akutbakker refererer til bakker/kasser med lægemidler og sygeplejeeartikler, der anvendes i akutte situationer såsom hjertestop. Alle spørgsmålene skal besvares, før spørgeskemaet kan gemmes.

Oplever I udfordringer ved implementering af nye Amgros-udbud i akutbakkerne?

- [ ] Ja
- [ ] Nej

Hvilke udfordringer oplever I?

- [ ] Pladsmangel i akutbakkerne
- [ ] Nyt lægemiddel passer ikke i skumindlæg
- [ ] Kassation af nuværende lægemiddel
- [ ] Merarbejdsomkostninger ved lægemiddelskift
- [ ] Andre

Hvilke andre udfordringer oplever I?

Har I en arbejdsgang/instruktion for håndtering af nye Amgros-udbud ift. akutbakkerne?

○ Ja
○ Nej
Hvilke parametre indgår i jeres arbejdsgang/instruktion for håndtering af nye Amgros-udbud?

- Pris for nuværende lægemiddel i ny Amgros-periode
- Lagerstatus for nuværende lægemiddel
- Udløb for nuværende lægemiddel på lager
- Udløb for nuværende lægemiddel i akutbakternerne
- Pris for nyt lægemiddel
- Arbejdstid for opdatering af nye arbejdssedler
- Antal potentielle lægemiddelskift i den specifikke akutbakke
- Potentiel udskiftning af emballage (inkl. skumindlæg m.m.)
- Forventet lægemiddelforbrug i ny Amgros-periode
- Antal af den specifikke akutbakke i omløb
- Årlig ompakningsfrekvens af den specifikke akutbakke (ift. udløb)
- Andre parametre

Nuværende lægemiddel: Lægemiddel i akutbakternerne nu. Nyt lægemiddel: Lægemiddel, som har vundet udbuddet for ny Amgros-periode
Hvilke andre parametre indgår i jeres arbejdsgang/instruktion?

| Hvilke andre parametre indgår i jeres arbejdsgang/instruktion? |
Hvilke parametre indgår i jeres overvejelser om implementering af nye Amgros-udbud?

- Pris for nuværende lægemiddel i ny Amgros-periode
- Lagerstatus for nuværende lægemiddel
- Udløb for nuværende lægemiddel på lager
- Udløb for nuværende lægemiddel i akutbakkerne
- Pris for nyt lægemiddel
- Arbejdstid for opdatering af nye arbejdssedler
- Antal potentielle lægemiddelskift i den specifikke akutbakke
- Potentiel udskiftning af emballage (inkl. skumindlæg m.m.)
- Forventet lægemiddelforbrug i ny Amgros-periode
- Antal af den specifikke akutbakke i omløb
- Årlig ompakningsfrekvens af den specifikke akutbakke (ift. udløb)
- Andre parametre

Nuværende lægemiddel: Lægemiddel i akutbakkerne nu. Nyt lægemiddel: Lægemiddel, som har vundet udbuddet for ny Amgros-periode
Hvilke andre parametre indgår i jeres overvejelser?

Hvis I har noteret hvilke overvejelser, I gør jer ved håndtering af nye Amgros-udbud i akutbakterne, bedes I venligst opsummere disse
Tilbagekalder I de akutbakker, der er i omløb, når I implementerer nye Amgros-udbud?

- Ja, altid
- Ja, hvis omkostningerne er tilstrækkelig lave
- Nej

Tydeliggør I lægemiddelskift i akutbakkerne for kunden?

- Ja
- Nej

Hvordan tydeliggør I lægemiddelskift i akutbakkerne?
Har I nogle kommentarer eller tilføjelser?

Venligst angiv e-mailadresse og telefonnummer på en kontaktperson, således vi har mulighed for at stille afklarende spørgsmål
Appendix II - Calculations Included in the Tool

The appendix illustrates the functions used to create the economic calculation tool for EDKs.

Functions
The statistical functions MIN and MAX are used to create the calculations.

The syntax of the MIN function is MIN(number 1, [number 2],…), and it returns the smallest value from the numbers provided.

The syntax of the MAX function is MAX(number 1, [number 2],…), and it returns the largest value from the numbers provided.

Current drug
Drug costs

Total drug costs = MAX((predicted yearly demand − stock status) · price of the drug in new Amgros period, 0)

Labor costs

New worksheets = \frac{EDKs \text{ in circulation}}{columns \text{ to document refilling on worksheet}}

Work hours for transfer of data to worksheets = \frac{new \text{ worksheets} \cdot minutes \text{ for transfer of data to worksheet}}{60}

Labor costs for transfer of data to worksheets = work hours for transfer of data to worksheets \cdot hourly wage
**Total costs**

Price of keeping the current drug = total drug costs + labor costs for transfer of data to worksheets

**New drug**

**Drug costs**

Extra consumption due to refilling of EDK = \( \text{MIN} \left( \frac{\text{EDKs in circulation}}{\text{shelf life of the EDK after refilling}}, 0 \right) \) \cdot \text{Components of the drug in the EDK}

Total drug costs = (predicted yearly demand + extra consumption due to refilling of EDK) \cdot \text{price of the drug}

**Labor costs**

New worksheets = \( \text{MIN} \left( \frac{\text{EDKs in circulation}}{\frac{\text{shelf life of the EDK after refilling}}{12}}, \text{EDKs in circulation} \right) \)

Work hours for transfer of data to worksheets = \( \frac{\text{new worksheets} \cdot \text{minutes for transfer of data to worksheet}}{60} \)

Labor costs for transfer of data to worksheets = work hours for transfer of data to worksheets \cdot \text{hourly wage}
**Total costs**

Price of replacing the current drug with the new drug

\[
= \text{total drug costs} + \text{labor costs for transfer of data to worksheets} + \text{total price for new packaging} + \text{basic costs}
\]

**Additional costs or savings for replacing the current drug with the new drug**

Additional costs or savings \(=\) price of replacing the current drug with new new drug \(-\) price of keeping the current drug

If the outcome is negative, replacing the current drug with the new drug results in savings for the hospital pharmacy. If the outcome is positive, replacing the current drug with the new drug results in additional costs for the hospital pharmacy.

When using the tool, savings are not represented by a negative outcome. Instead the tool provides information of whether the outcome is a saving or an additional cost.
Appendix III - Additional Results

This appendix provides the results of the questionnaire not included in the article. They concern the customers of the hospital pharmacies, the feedback the hospital pharmacies have received along with information about how the hospital pharmacies notify the hospitals about drug replacements in the EDKs. Furthermore, the assortment and different types of EDKs are elaborated.

Customers

The main customers of the hospital pharmacies are the local hospitals. Beyond that, three of the hospital pharmacies responded that they deliver EDKs to other customers composed of emergency medical services (Falck), local homecare services, private pharmacies, and Greenland. The packaging of EDKs to the other customers is mainly single-use except for those to the emergency medical services, which are reusable.

Feedback

Five hospital pharmacies have received feedback from their customers related to the EDKs. Three of them reported feedback related to one of the following: problems with labels, disorganized arrangement of drugs, and risks of confusion between the drugs in the kits. The additional two hospital pharmacies reported that the feedback involved requests for revision of the content along with a longer shelf life of the kits.

Notifications about Drug Replacements

Seven of the hospital pharmacies provide their customers with additional information during drug replacements in the EDKs. The information provided from the different hospital pharmacies includes a combination of informing the hospital wards prior to the drug replacement and attaching additional instructions in the kits along with extra labelling. One of the hospital pharmacies pointed out that if the change is to another brand name, it is not always relevant to provide additional information.
The assortment of EDKs

In total, the entire assortment of EDKs produced at the hospital pharmacies includes 58 kits. Fig. 1 illustrates the total number of produced kits within each category (and not the quantity of hospital pharmacies that produce them).

Figure 1: The assortment of EDKs. The figure illustrates the distribution of single-use and reusable packaging for the different types of EDKs. The Mixed EDKs category illustrates the quantity of EDKs that contain drugs used for multiple types of emergencies. EDK: Emergency drug kit.

The EDKs for cardiac arrest are generally similar; however, one of the hospital pharmacies produces three different EDKs for cardiac arrest termed regular, diverse, and supplement medicine for cardiac emergencies. Drugs utilized for anaphylactic shock, allergic reactions, and anaphylaxis are included in the EDKs for anaphylactic shock, whereas the EDKs for convulsions contain drugs utilized to treat seizures such as epileptic convulsions, epileptic state, or fever cramps. The EDKs used for emergencies during patient transportation include drugs for different emergencies such as cardiac arrest, convulsions, anaphylactic shock, and drug overdoses. Drugs of vital importance during anesthetic procedures are included in the EDKs for anesthesia. These drugs can prevent or treat anaphylactic shock, cardiac arrest, or malignant hyperthermia, which are potential serious complications to the anesthetics. Kits used for preeclampsia, eclampsia, postpartum bleeding, and home birth are covered by the EDKs for pregnancy and birth, whereas emergencies such as cardiac arrest and anaphylactic shock occurring in neonates and children are included in the EDKs for neonates and children. The kits that each include drugs for several emergencies are covered by the mixed EDKs, whereas kits that simply contain utensils or magnesium sulphate along with kits utilized during intubation are included in the other category.
Appendix IV - The Economic Calculation Tool for EDKs

The following link provides access to the economic calculation tool for EDKs along with an example of replacing Solu-Medrol® with Depo-Medrol®.

https://www.dropbox.com/sh/ji9pemq3mmq04fx/AAAtOa-GlqvchZWoiJw84Ga?dl=0

A screenshot of the tool filled-in with the example is shown in Fig. 1 on the next page. The example illustrates the values of all the parameters along with the economic outcomes of replacing Solu-Medrol® with Depo-Medrol® in the EDK for anaphylactic shock during the Amgros-tender in 2016. The drug replacement was considered too expensive to complete at the Hospital Pharmacy in the North Denmark Region.
Figure 1: Economic outcomes of replacing Solu-Medrol® with Depo-Medrol®.

<table>
<thead>
<tr>
<th></th>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Beregnning for skift af ét lægemiddel</td>
<td></td>
<td></td>
<td>NUÆREnde LÆGEMIDDel</td>
<td>RESULTAT FOR SKIFT AF ET LÆGEMIDDel</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>Udfyld nedenstående felt</td>
<td>Total lægemiddelpris (kr.)</td>
<td>Totalomkostning for at beholde nuærende lægemiddel</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td>7.170,00 kr.</td>
<td>15.195,00 kr.</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>Nuærende lægemiddel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>Handelsnavn</td>
<td></td>
<td>Nuærende lægemiddel</td>
<td>Nye arbejdsdøyer (st. k.)</td>
<td>Totalomkostning for at skifte til nyt lægemiddel</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td>100</td>
<td>198.195,00 kr.</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td>478</td>
<td></td>
<td>Arbejdstid for overførsel til nye arbejdsdøyer (t.)</td>
<td>198.195,00 kr.</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td>15</td>
<td></td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Nyt lægemiddel</td>
<td></td>
<td></td>
<td>Totalomkostninger (kr.)</td>
<td>Meromkostning ved at skifte til nyt lægemiddel</td>
</tr>
<tr>
<td>11</td>
<td>Handelsnavn</td>
<td></td>
<td></td>
<td>8.025,00 kr.</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td>15.195,00 kr</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Almene faktorer</td>
<td></td>
<td></td>
<td>NYT LÆGEMIDDel</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Forventet årligt tørtvugt (st. k.)</td>
<td></td>
<td></td>
<td>Ekstra forbrug pga. genoplydning (st. k.)</td>
<td>600</td>
</tr>
<tr>
<td>18</td>
<td>Akuttakn (omløb) (st. k.)</td>
<td></td>
<td></td>
<td>Total lægemiddelpris (kr.)</td>
<td>172.620,00 kr.</td>
</tr>
<tr>
<td>19</td>
<td>Håndværker på akuttaget efter genoplydning (mdr.)</td>
<td></td>
<td></td>
<td>Nye arbejdsdøyer (st.)</td>
<td>300</td>
</tr>
<tr>
<td>20</td>
<td>Enheder af lægemiddel i akuttaget (st. k.)</td>
<td></td>
<td></td>
<td>Arbejdstid for overførsel til nye arbejdsdøyer (t.)</td>
<td>75</td>
</tr>
<tr>
<td>21</td>
<td>Kolonnér på arbejdsdøyer (st. k.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Arbejdstid for overførsel til arbejdsdøyer (min.)</td>
<td></td>
<td></td>
<td>Lænomkostninger (kr.)</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Arbejdstid for overførsel til arbejdsdøyer (t.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Tid (min.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td>24.075,00 kr.</td>
<td></td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td>198.195,00 kr.</td>
<td></td>
</tr>
<tr>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td>165.450,00 kr.</td>
<td></td>
</tr>
<tr>
<td>33</td>
<td></td>
<td></td>
<td></td>
<td>16.050,00 kr.</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td></td>
<td></td>
<td></td>
<td>Besparelse/meromkostning ved at skifte (kr.)</td>
<td>183.000,00 kr.</td>
</tr>
<tr>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Appendix V - Vejledning til brug af Excel-værktøjet

_Dette værkøj er lavet til internt brug på Sygehusapoteket Region Nordjylland._

Excel-værktøjet bør anvendes som et redskab til at beregne de økonomiske omkostninger (baseret på 1 års forbrug) for implementering af nye Amgros-udbud i akutbakkerne. Ved at indtaste værdierne for parametrene udregnes de økonomiske udfald for at beholde det nuværende lægemiddel’ og at udskifte til det nye lægemiddel”*, som har vundet Amgros-udbudet. Samtlige felter på nær _total pris for ny emballage_ skal udfyldes før priserne kan beregnes.

En betingelse for at anvende værktøjet er, at det nuværende lægemiddel _ikke_ udgår i den nye Amgros-periode. Hvis der indgår flere potentielle lægemiddelskift i _samme type_ akutbakke udfyldes et Excel-ark for hvert lægemiddel. For at få den totale meromkostning/besparelse for at udskifte samtlige lægemidler i akutbakken gøres flg.: Hvis værdien i celle E10 for det ene lægemiddel er en meromkostning, lægges denne sammen med værdien i celle D18 for de andre lægemidler. Derimod, hvis værdien i celle E10 for det ene lægemiddel er en besparelse, trækkes værdien i celle D18 for de andre lægemidler fra værdien i celle E10.

Mellemregningerne er tilgængelige i kolonne D, som kan vises ved at højreklikke på kolonnen og trykke på _Vis_. Værktøjet er skrivebeskyttet for at minimere risikoen for fejl, men kan låses op via flg. kode: 859478

’* Nuværende lægemiddel kendetegner det præparat som allerede indgår i akutbakken.

”** Nyt lægemiddel kendetegner det synonympræparat, som er billigst i den nye Amgros-periode.

**Nuværende lægemiddel**

Felte B6-B8 i Excel-arket udfyldes med værdierne for de angivne parametre for det nuværende lægemiddel. Parametrene er som følger:

- **Handelsnavn**
- **Pris i ny Amgros-periode (kr./stk.):** Prisen pr. enhed (enkeltstyks).
- **Lagerstatus (stk.):** Mængden af lægemidlet på lager som kan holde sig i min. 1 år.

**Nyt lægemiddel**

Felte B11-B14 i Excel-arket udfyldes med værdierne for de angivne parametre for det nye lægemiddel. Parametrene er som følger:
- **Handelsnavn**
- **Pris (kr./stk.):** Prisen pr. enhed (enkeltyks).
- **Totalpris for ny emballage (kr.):** Denne parameter inkluderer bl.a. nye skumindlæg.
  
  **OBS:** Udfyld kun hvis der er behov for indkøb af ny emballage. Totalprisen kan evt. beregnes på flg. måde:
  \[
  \text{Totalpris} = \text{pris for emballage pr. akutbakke} \times (\text{antal akutbakker i omløb og på lager} + 10 \% \text{ ekstra})
  \]

- **Grundomkostninger (kr.):** Dækker standardudgifter som f.eks. opdatering og kvalitetssikring af etiketter og arbejdssedler samt print heraf. Denne parameter er skønnet til 1500 kr. NB: For hvert ekstra lægemiddelskift i akutbakken bør tillægges 10 % af denne omkostning.

**Almene faktorer**

Felte B17-B23 i Excel-arket udfyldes med værdierne for de angivne parametre, som gør sig gældende for både det nuværende- og nye lægemiddel. Parametrene er som følger:

- **Forventet årligt forbruget (stk.):** Det totale forbrug baseret på konsumption og forbrug af lægemidlet grundet udløb af lægemidlet i den nye Amgros-periode.
- **Akutbakker i omløb (stk.):** Antallet af den specifikke type akutbakke (akutbakke med samme vnr.) som er i omløb.
- **Holdbarhed af akutbakken efter genopfyldning (mdr.):** Hvor mange måneder akutbakken kan holde sig efter genopfyldning - baseret på bakkens udløbsdato.
- **Enheder af lægemidlet i akutbakken (stk.):** Hvor mange enheder af lægemidlet der indgår i hver enkelt akutbakke.
- **Kolonner på arbejdsseddel (stk.):** Det totale antal kolonner på arbejdssedlen der bruges til at dokumentere genopfyldning af akutbakken. Denne parameter er sat til 3.
- **Arbejdstid for overførsel til arbejdsseddel (min.):** Arbejdstid afsat til at en medarbejder kan overføre batchnumre og lign. for lægemidlerne i akutbakken til en ny arbejdsseddel. Denne parameter er sat til 15 min.
- **Timeløn (kr.):** Timelønnen for at pakke akutbakker. Denne parameter er sat til 321 kr. og er baseret på lønnen for en farmakonom/laborant.
Værktøjets funktion og begrænsninger


Illustration af værktøjet

<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
<th>E</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Beregning for skift af et lægemiddel</td>
<td></td>
<td>NUÆREnde LÆGEMIDDEL</td>
<td>RESULTAT FOR SKIFT AF ET LÆGEMIDDEL</td>
</tr>
<tr>
<td>2</td>
<td>Akutbakkenummer (Vnr.)</td>
<td>802692</td>
<td>Total lægemiddelpris (kr.)</td>
<td>7.170,00 kr.</td>
</tr>
<tr>
<td>3</td>
<td>Nuærende lægemiddel</td>
<td></td>
<td>Nye arbejdssedler (stk.)</td>
<td>15 195,00 kr.</td>
</tr>
<tr>
<td>4</td>
<td>Handelsnavn</td>
<td>Solu-Medrol</td>
<td>Totalomkostning for at beholde nuærende lægemiddel</td>
<td>15 195,00 kr.</td>
</tr>
<tr>
<td>5</td>
<td>Pris i ny Angros-periode (kr./stk.)</td>
<td>478</td>
<td>Arbejdstid for overførsel til nye arbejdssedler (t.)</td>
<td>15 198,155,00 kr.</td>
</tr>
<tr>
<td>6</td>
<td>Lagerstatus (stk.)</td>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td>Lønomkostninger (kr.)</td>
<td>8 025,00 kr.</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td>Meromkostning ved at skifte til nyt lægemiddel</td>
<td>183 000,00 kr.</td>
</tr>
<tr>
<td>9</td>
<td>Nyt lægemiddel</td>
<td></td>
<td>Totalomkostninger for at beholde (kr.)</td>
<td>15 195,00 kr.</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Handelsnavn</td>
<td>Depo-Medrol</td>
<td>NYT LÆGEMIDDEL</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>Pris (kr./stk.)</td>
<td>274</td>
<td>Ekstra forbrug pga. genopfyldning (stk.)</td>
<td>600</td>
</tr>
<tr>
<td>13</td>
<td>Totalpris for ny emballage (kr.)</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Grundomkostninger (kr.)</td>
<td>1500</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td>NYT LÆGEMIDDEL</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Almene faktorer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Forventet årligt forbrug (stk.)</td>
<td>30</td>
<td>Total lægemiddelpris (kr.)</td>
<td>172 620,00 kr.</td>
</tr>
<tr>
<td>18</td>
<td>Akutbakker i omelb (stk.)</td>
<td>300</td>
<td>Nye arbejdssedler (stk.)</td>
<td>300</td>
</tr>
<tr>
<td>19</td>
<td>Holdbarhed af akutbakken efter genopfyldning (mdr.)</td>
<td>6</td>
<td>Arbejdstid for overførsel til nye arbejdssedler (t.)</td>
<td>75</td>
</tr>
<tr>
<td>20</td>
<td>Enheder af lægemiddel i akutbakken (stk.)</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Koster på arbejdsseddel (stk.)</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Arbejdstid for overførsel til arbejdsseddel (min.)</td>
<td>15</td>
<td>Lønomkostninger (kr.)</td>
<td>24 075,00 kr.</td>
</tr>
<tr>
<td>23</td>
<td>Tid mel. (kr.)</td>
<td>321</td>
<td>Totalomkostninger for at skifte (kr.)</td>
<td>198 195,00 kr.</td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td>DIFFERENCE (NYT LÆGEMIDDEL-NUÆREnde LÆGEMIDDEL)</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>Lægemiddelpris (kr.)</td>
<td>155 450,00 kr.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td>Lønomkostninger (kr.)</td>
<td></td>
<td>36 050,00 kr.</td>
<td></td>
</tr>
<tr>
<td>32</td>
<td>Besparelse/meromkostning ved at skifte (kr.)</td>
<td>183 000,00 kr.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>